Tirzepatide vs Mazdutide

The two leading dual-agonist incretins, one western (GIP+GLP-1), one Asia-first (GLP-1+glucagon). What their trials actually show.

Both are dual-receptor incretin agonists — but they pair GLP-1 with different second receptors. Tirzepatide adds GIP; mazdutide adds glucagon. Trial cohorts differ substantially, which matters when comparing headline efficacy numbers.

Side-by-side comparison

	Tirzepatide	mazdutide
Class	Dual GIP / GLP-1 agonist	Dual GLP-1 / glucagon agonist
Receptors activated	2 (GIP + GLP-1)	2 (GLP-1 + glucagon)
FDA status	Approved (Mounjaro, Zepbound)	Investigational (approved in China 2025)
Headline trial	SURMOUNT-1 (72 wk)	GLORY-1 (48 wk)
Average weight reduction	~20–22%	~15–18%
Mechanistic differentiator	GIP-driven insulin sensitivity + appetite	Glucagon-driven energy expenditure

About Tirzepatide

Tirzepatide is a synthetic peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The dual-incretin profile has drawn significant clinical and research interest.

By engaging GIP and GLP-1 receptors simultaneously, tirzepatide influences insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.

• Metabolic and body-composition research
• Glycemic control studies
• Comparative incretin pharmacology

The takeaway

Tirzepatide currently leads on absolute weight-loss numbers in western trials. Mazdutide's glucagon-arm may offer different metabolic effects (hepatic fat, energy expenditure); head-to-head data is not yet available.

How to read this comparison

The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.

• Check which compound has approved clinical use for the indication you care about, and which does not.
• Compare half-life and dosing cadence against how consistently a protocol can actually be followed.
• Read both individual reference pages before drawing a conclusion from the table alone.
• Any clinical decision belongs with a licensed practitioner who knows the full history.

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.

Frequently asked questions

Is tirzepatide stronger than semaglutide?

Head-to-head clinical trials (SURPASS-2) suggest greater average weight reduction with tirzepatide, but individual response varies and any clinical decision should be made with a licensed provider.

What does 'dual agonist' actually mean?

Tirzepatide activates two receptors (GIP and GLP-1) on the same molecule, in contrast to semaglutide which targets only GLP-1.